Trial Profile
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 26 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2022 Planned End Date changed from 1 Nov 2021 to 1 May 2023.
- 06 Jul 2022 Planned primary completion date changed from 1 Nov 2021 to 1 May 2023.